HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer.

Abstract
For many inborn errors of metabolism, early treatment is critical to prevent long-term developmental sequelae. We have previously shown that systemic treatment of neonatal mucopolysaccharidosis type VII (MPS VII) mice with recombinant adeno-associated virus (AAV) vectors results in relatively long-term expression of beta-glucuronidase (GUSB) in multiple tissues, and a reduction in lysosomal storage. Here, we demonstrate that therapeutic levels of enzyme persist for at least 1 year following a single intravenous injection of virus in neonatal MPS VII mice. The level and distribution of GUSB expression achieved is sufficient to prevent the development of many aspects of clinical disease over the life of the animal. Following treatment, bone lengths, weights and retinal function were maintained at nearly normal levels throughout the life of the animal. In addition, significant improvements in survival and auditory function were seen in AAV-treated MPS VII mice when compared with untreated mutant siblings. These data suggest that AAV-mediated gene transfer in the neonatal period can lead to prevention of many of the clinical symptoms associated with MPS VII in the murine model of this disease.
AuthorsT M Daly, K K Ohlemiller, M S Roberts, C A Vogler, M S Sands
JournalGene therapy (Gene Ther) Vol. 8 Issue 17 Pg. 1291-8 (Sep 2001) ISSN: 0969-7128 [Print] England
PMID11571565 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Glucuronidase
Topics
  • Animals
  • Animals, Newborn
  • Deafness (physiopathology)
  • Electroretinography
  • Evoked Potentials, Auditory, Brain Stem
  • Gene Expression
  • Genetic Therapy (methods)
  • Glucuronidase (genetics)
  • Mice
  • Mice, Mutant Strains
  • Models, Animal
  • Mucopolysaccharidosis VII (enzymology, physiopathology, therapy)
  • Retina (physiopathology)
  • Survival Rate
  • Transduction, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: